Advertisement News Archives - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

News

March 22, 2023

FDA grants fast track status to Prestige’s PBP1510 for pancreatic cancer

The US Food and Drug Administration has granted fast track designation to Prestige Biopharma’s PBP1510 (Ulenistamab) to treat unresectable or metastatic pancreatic adenocarcinoma (PDAC).

FDA grants fast track status to Prestige’s PBP1510 for pancreatic cancer